Alkem Laboratories Ltd
About
With over 19 manufacturing units and 800 brands spread over 40 countries, Alkem Laboratories is one of the leaders in the Indian pharmaceutical sector. The company produces generics, branded generics, over-the-counter (OTC) products, active pharmaceutical ingredients (APIs), and nutraceuticals in the form of capsules, tablets, powders, liquids, and injectables. Its offerings cover therapeutic areas like anti-infective, gastroenterology, pain relief/analgesic, anti-diabetic, cardiology, dermatology, neurology/central nervous system, and vitamins, minerals, and nutrition. Alkem marks its presence in countries like the UK, Brazil, Germany, and South Africa through regulatory approvals by their medical agencies. Some of Alkem’s prominent brands in India include Pan, Pan-D, Clavam, and Taxim-O.
Featured In Fortune India Ranking
Financial Data 2024
Fortune India Coverage
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 12964 14.2% | 11353 0.2% | 11332 20.2% | 9432 8.7% | 8679 16.6% | 7441 12.6% | 6612 8.6% | 6089 15.6% | 5269 33.1% | 3958 18.5% | 3341 19.2% | 2804 23.2% | 2275 25.5% | 1813 29.7% | 1398 15.0% | 1216 - |
| Net Operating Income (INR Cr) | 12668 9.21% | 11599 9.08% | 10634 19.96% | 8865 6.24% | 8344 13.42% | 7357 14.94% | 6401 12.55% | 5688 15.49% | 4925 31.56% | 3743 19.75% | 3126 25.28% | 2495 23.79% | 2016 19.21% | 1691 0.00% | 1344 15.82% | 1160 18.89% |
| Profit (INR Cr) | 1796 82.5% | 984 -40.2% | 1646 3.8% | 1585 40.6% | 1127 48.2% | 761 20.5% | 631 -29.3% | 892 20.3% | 742 89.4% | 392 -10.1% | 435 13.4% | 384 -5.6% | 407 37.5% | 296 24.2% | 238 50.5% | 158 - |
| Assets (INR Cr) | 12770 12.3% | 11376 -4.1% | 11856 23.4% | 9610 16.6% | 8243 23.0% | 6703 9.0% | 6147 14.8% | 5356 18.2% | 4530 1.4% | 4466 18.7% | 3763 -0.6% | 3785 25.9% | 3007 20.0% | 2507 96.7% | 1275 -8.2% | 1388 - |
| Net Worth (INR Cr) | 10312 14.0% | 9045 4.7% | 8638 17.1% | 7377 19.7% | 6161 13.3% | 5439 11.8% | 4864 8.9% | 4468 21.0% | 3692 23.1% | 2999 16.3% | 2579 18.8% | 2172 19.7% | 1814 27.1% | 1428 0.0% | 1205 22.4% | 985 16.3% |
| Employee Cost (INR Cr) | 2201 3.3% | 2131 8.6% | 1963 21.1% | 1621 7.7% | 1505 10.5% | 1362 14.3% | 1192 18.7% | 1004 16.6% | 861 33.3% | 646 21.5% | 532 28.9% | 412 35.9% | 303 13.6% | 267 48.0% | 181 41.2% | 128 - |
| Interest Cost (INR Cr) | 112 | 107 | 52 | 59 | 65 | 55 | 55 | 45 | 71 | 81 | 93 | 88 | 58 | 41 | 20 | 15 |
| Cash & Bank Balance (INR Cr) | 1579 | 2617 | 2579 | 1990 | 1092 | 662 | 577 | 399 | 781 | 791 | 206 | 995 | 514 | 990 | 662 | 728 |
| Total Debt (INR Cr) | 1418 | 1397 | 2668 | 1792 | 1616 | 944 | 998 | 659 | 658 | 1306 | 1128 | 1552 | 1007 | 909 | 70 | 403 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 13.9% | 8.7% | 14.5% | 16.8% | 13.0% | 10.2% | 9.5% | 14.7% | 14.1% | 9.9% | 13.0% | 13.7% | 17.9% | 16.3% | 17.0% | 13.0% |
| Profit As % Of Assets | 14.1% | 8.7% | 13.9% | 16.5% | 13.7% | 11.4% | 10.3% | 16.7% | 16.4% | 8.8% | 11.6% | 10.1% | 13.5% | 11.8% | 18.7% | 11.4% |
| Profit As % Of Networth | 17.4% | 10.9% | 19.1% | 21.5% | 18.3% | 14.0% | 13.0% | 20.0% | 20.1% | 13.1% | 16.9% | 17.7% | 22.4% | 20.7% | 19.8% | 16.1% |
| Interest Cost to EBITDA % | 5.3% | 7.1% | 2.6% | 3.0% | 4.4% | 4.9% | 5.5% | 4.5% | 8.4% | 19.2% | 22.7% | 24.3% | 15.5% | 14.4% | 9.8% | 10.1% |
| Debt to Equity Ratio | 0.14 | 0.15 | 0.31 | 0.24 | 0.26 | 0.17 | 0.21 | 0.15 | 0.18 | 0.44 | 0.44 | 0.71 | 0.56 | 0.64 | 0.06 | 0.41 |
| RONW | 18.7% | 11.4% | 21.0% | 23.9% | 19.8% | 15.0% | 13.7% | 22.2% | 22.5% | 14.0% | 18.3% | 19.3% | 25.0% | 20.7% | 21.7% | 17.3% |
| ROCE | 18.3% | 12.5% | 18.0% | 21.7% | 18.1% | 16.0% | 17.4% | 20.9% | 22.7% | 13.1% | 13.9% | 14.4% | 17.8% | 14.9% | 19.9% | 14.6% |